Abstract
Objective
Characterize association between hydrocortisone receipt and hospital outcomes of infants with persistent pulmonary hypertension of the newborn (PPHN).
Study design
Cohort study of infants ā„34 weeks with PPHN who received inhaled nitric oxide at <7 days of age (2010ā2016). We generated propensity scores, and performed inverse probability-weighted regression to estimate hydrocortisone effect on outcomes: death, chronic lung disease (CLD), oxygen at discharge.
Results
Of 2743 infants, 30% received hydrocortisone, which was associated with exposure to mechanical ventilation, sedatives, paralytics, or vasopressors (pā<ā0.001). There was no difference in death, CLD, or oxygen at discharge. In infants with meconium aspiration syndrome, hydrocortisone was associated with decreased oxygen at discharge (odds ratio 0.56; 95% confidence interval 0.21, 0.91).
Conclusions
There was no association between hydrocortisone receipt and death, CLD, or oxygen at discharge in our cohort. Prospective studies are needed to evaluate the effectiveness of hydrocortisone in infants with PPHN.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fuloria M, Aschner JL. Persistent pulmonary hypertension of the newborn. Semin Fetal Neonatal Med. 2017;22:220ā6.
Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105:14ā20.
Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The inhaled nitric oxide study group. N Engl J Med. 1997;336:605ā10.
Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical inhaled nitric oxide research group. N Engl J Med. 2000;342:469ā74.
Neonatal Inhaled Nitric Oxide Study G. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597ā604.
Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2017;1:CD000399.
Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117:1077ā83.
McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21:217ā22.
Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol. 2012;32:608ā13.
Farrow KN, Steinhorn RH. Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension. In: Francis S, Conti M, Houslay M, editors. Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology, vol. 204. Heidelberg, Berlin: Springer; 2011.
Lakshminrusimha S, Russell JA, Steinhorn RH, Ryan RM, Gugino SF, Morin FC 3rd, et al. Pulmonary arterial contractility in neonatal lambs increases with 100% oxygen resuscitation. Pediatr Res. 2006;59:137ā41.
Lakshminrusimha S, Steinhorn RH, Wedgwood S, Savorgnan F, Nair J, Mathew B, et al. Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100% oxygen. J Appl Physiol. 2011;111:1441ā7.
Perez M, Lakshminrusimha S, Wedgwood S, Czech L, Gugino SF, Russell JA, et al. Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol. 2012;302:L595ā603.
Perez M, Wedgwood S, Lakshminrusimha S, Farrow KN, Steinhorn RH. Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn. Pulm Circ. 2014;4:71ā81.
Byers HM, Dagle JM, Klein JM, Ryckman KK, McDonald EL, Murray JC, et al. Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn. Pediatr Res. 2012;71:162ā7.
Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system-tools for āmeaningful useā in continuous quality improvement. Clin Perinatol. 2010;37:49ā70.
Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163:955ā60.e1.
Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics. 2010;125:e214ā24.
Imai K, Ratkovic M. Covariate balancing propensity score. J R Stat Soc Ser B. 2014;76:243ā63.
Pierro M, Thebaud B. Understanding and treating pulmonary hypertension in congenital diaphragmatic hernia. Semin Fetal Neonatal Med. 2014;19:357ā63.
Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014;38:78ā91.
Lakshminrusimha S, Mathew B, Leach CL. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Semin Perinatol. 2016;40:160ā73.
Mathew B, Lakshminrusimha S. Persistent pulmonary hypertension in the newborn. Children. 2017;4:63.
Fernandez E, Schrader R, Watterberg K. Prevalence of low cortisol values in term and near-term infants with vasopressor-resistant hypotension. J Perinatol. 2005;25:114ā8.
Baker CF, Barks JD, Engmann C, Vazquez DM, Neal CR Jr, Schumacher RE, et al. Hydrocortisone administration for the treatment of refractory hypotension in critically ill newborns. J Perinatol. 2008;28:412ā9.
Alsaleem M, Malik A, Lakshminrusimha S, Kumar VH. Hydrocortisone improves oxygenation index and systolic blood pressure in term infants with persistent pulmonary hypertension. Clin Med Insights Pediatr. 2019;13:1179556519888918.
Tripathi S, Saili A. The effect of steroids on the clinical course and outcome of neonates with meconium aspiration syndrome. J Trop Pediatr. 2007;53:8ā12.
Basu S, Kumar A, Bhatia BD, Satya K, Singh TB. Role of steroids on the clinical course and outcome of meconium aspiration syndrome-a randomized controlled trial. J Trop Pediatr. 2007;53:331ā7.
Mokra D, Mokry J. Glucocorticoids in the treatment of neonatal meconium aspiration syndrome. Eur J Pediatr. 2011;170:1495ā505.
Soukka H, Halkola L, Aho H, Rautanen M, Kero P, Kaapa P. Methylprednisolone attenuates the pulmonary hypertensive response in porcine meconium aspiration. Pediatr Res. 1997;42:145ā50.
Funding
This work was supported by Duke Clinical Research Instituteās R25 Summer Training in Academic Research (STAR) Program (grant #5R25HD076475-07). This work was partially funded under the National Institute of Child Health and Human Development (NICHD) contract (HHSN275201000003I) for the Pediatric Trials Network (PI Danny Benjamin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Contributions
SA is the guarantor who accepts full responsibility for the work and conduct of the study, and had access to the data. SA conceptualized and designed the study, and contributed to the data interpretation, the drafting of the initial paper, and reviewing and revising the paper. CR contributed to the data interpretation and the paper drafting. BM contributed to the data interpretation and the paper drafting. SE contributed to the data interpretation and the paper drafting. CA contributed to the data interpretation and the paper drafting. NP contributed to the data interpretation and the paper drafting. DKB contributed to the study design, data analyses, and the critical revision of the paper for important intellectual content. VNT contributed to the data interpretation and the critical revision of the paper for important intellectual content. KOZ contributed to the data interpretation and the critical revision of the paper for important intellectual content. RNG contributed to the data interpretation and the critical revision of the paper for important intellectual content. RGG contributed to the conception and design of the study, supervised the drafting of the paper, interpreted the data analyses, and reviewed and revised the paper. RGG had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Corresponding author
Ethics declarations
Conflict of interest
RGG has received support from industry for research services (https://dcri.org/about-us/conflict-of-interest/). The other authors have no competing interests relevant to this article to disclose.
Additional information
Publisherās note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Aleem, S., Robbins, C., Murphy, B. et al. The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn. J Perinatol 41, 794ā800 (2021). https://doi.org/10.1038/s41372-021-00943-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-021-00943-9